Plasticity and biological diversity of myeloid derived suppressor cells

Current Opinion in Immunology

Volumn 51, Issue , 2018, Pages 154-161

  Ben Meir, Kerem ^a   Twaik, Nira ^a   Baniyash, Michal ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; ARGINASE 1; CELL SURFACE RECEPTOR; CHIMERIC ANTIGEN RECEPTOR; CYTOSTATIC AGENT; ETOMOXIR; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROGRAMMED DEATH 1 LIGAND 1; RAPAMYCIN; REACTIVE NITROGEN SPECIES; RETINOIC ACID; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER;

ALLOTRANSPLANTATION; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CELL FATE; CELL PLASTICITY; CHRONIC INFLAMMATION; CYTOKINE RELEASE; EXOSOME; FATTY ACID OXIDATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; METASTASIS; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; BIODIVERSITY; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; BIODIVERSITY; BIOMARKERS; CELL PLASTICITY; COMBINED MODALITY THERAPY; EXOSOMES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 85044599039     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2018.03.015     Document Type: Review

References (53)

1. Baniyash, M., Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy. Cancer Immunol Immunother 65 (2016), 857–867.
2. Meirow, Y., Baniyash, M., Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases. Cancer Immunol Immunother 66 (2017), 1089–1101.
3. Gabrilovich, D.I., Myeloid-derived suppressor cells. Cancer Immunol Res 5 (2017), 3–8.
4. Bronte, V., Brandau, S., Chen, S.-H., Colombo, M.P., Frey, A.B., Greten, T.F., Mandruzzato, S., Murray, P.J., Ochoa, A., Ostrand-Rosenberg, S., et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun, 7, 2016, 12150.
5. Ouzounova, M., Lee, E., Piranlioglu, R., El Andaloussi, A., Kolhe, R., Demirci, M.F., Marasco, D., Asm, I., Chadli, A., Hassan, K.A., et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat Commun, 8, 2017, 14979 The authors show the M-MDSC and PMN-MDSC mediated regulation of tumor progression, along with MDSC plastic behavior during migration out of the BM, into the tumor and periphery.
6. Yamashita, T., Budhu, A., Forgues, M., Wang, X.W., Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67 (2007), 10831–10839.
7. Kumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L.R., McCaffrey, J.C., Hockstein, N., Guarino, M., Masters, G., Penman, E., et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44 (2016), 303–315.
8. Charles, J.F., Hsu, L.Y., Niemi, E.C., Weiss, A., Aliprantis, A.O., Nakamura, M.C., Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest 122 (2012), 4592–4605.
9. + osteoclasts that induced bone resorption.
10. Karakasheva, T.A., Waldron, T.J., Eruslanov, E., Lee, J.-S., O'Brien, S., Hicks, P.D., Basu, D., Singhal, S., Malavasi, F., Rustgi, A.K., CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer. Cancer Res, 75, 2015, 10.1158/0008-5472.CAN-14-3639.
11. Camacho-Pereira, J., Tarragó, M.G., Chini, C.C.S., Nin, V., Escande, C., Warner, G.M., Puranik, A.S., Schoon, R.A., Reid, J.M., Galina, A., et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab 23 (2016), 1127–1139.
12. Condamine, T., Dominguez, G.A., Youn, J.-I., Kossenkov, A.V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol, 1, 2016.
13. Lu, C., Redd, P.S., Lee, J.R., Savage, N., Liu, K., The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology, 5, 2016, e1247135.
14. Hossain, F., Al-Khami, A.A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L.D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 3 (2015), 1236–1247 This study along with Al-Khami et al. shows MDSC metabolic changes upon their infiltration into the tumor, a process determining their cellular fate and function.
15. •• ].
16. Wang, Y., Tian, J., Tang, X., Rui, K., Tian, X., Ma, J., Ma, B., Xu, H., Lu, L., Wang, S., et al. Exosomes released by granulocytic myeloid-derived suppressor cells attenuate DSS-induced colitis in mice. Oncotarget 7 (2016), 15356–15368 This paper reveals a new aspect of PMN-MDSC immunosuppressive activity mediated via secreted exosomes, which contain active Arg-1, and thus could be used to attenuate exacerbated immune response.
17. Geis-Asteggiante, L., Dhabaria, A., Edwards, N., Ostrand-Rosenberg, S., Fenselau, C., Top-down analysis of low mass proteins in exosomes shed by murine myeloid-derived suppressor cells. Int J Mass Spectrom 378 (2015), 264–269.
18. Deng, Z., Rong, Y., Teng, Y., Zhuang, X., Samykutty, A., Mu, J., Zhang, L., Cao, P., Yan, J., Miller, D., et al. Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis. Oncogene 36 (2017), 639–651.
19. Draghiciu, O., Lubbers, J., Nijman, H.W., Daemen, T., Myeloid derived suppressor cells — an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology, 4, 2015, e954829.
20. Sade-Feldman, M., Kanterman, J., Ish-Shalom, E., Elnekave, M., Horwitz, E., Baniyash, M., Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38 (2013), 541–554.
21. Long, A.H., Highfill, S.L., Cui, Y., Smith, J.P., Walker, A.J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M.G., Orentas, R.J., et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res 4 (2016), 869–880 This study emphasizes the importance of anti-MDSC treatments in combination with immune-based therapies. Combining ATRA and CAR T cell therapies significantly diminished the suppressiveness of MDSCs in the tumor environment and enhanced CAR T cells efficacy.
22. Ostrand-Rosenberg, S., Sinha, P., Figley, C., Long, R., Park, D., Carter, D., Clements, V.K., Frontline science: myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. J Leukoc Biol, 101, 2016, 10.1189/jlb.1HI1016-306RR This paper characterizes an evolutionary role for MDSCs as regulators of unwanted immune response during gestation and pregnancy.
23. Pan, T., Liu, Y., Zhong, L.M., Shi, M.H., Duan, X.B., Wu, K., Yang, Q., Liu, C., Wei, J.Y., Ma, X.R., et al. Myeloid-derived suppressor cells are essential for maintaining feto-maternal immunotolerance via STAT3 signaling in mice. J Leukoc Biol 100 (2016), 499–511.
24. − T cells by activation of the TGF-β/β-catenin pathway. Mol Hum Reprod 22 (2016), 499–511.
25. Zhu, M., Huang, X., Yi, S., Sun, H., Zhou, J., High granulocytic myeloid-derived suppressor cell levels in the peripheral blood predict a better IVF treatment outcome. J Matern Neonatal Med, 2017, 10.1080/14767058.2017.1400002.
26. Cavallaro, A., Lilleby, K., Majolino, I., Storb, R., Appelbaum, F., Rowley, S., Bensinger, W., Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 25 (2000), 85–89.
27. Tigue, C., Mckoy, J., Evens, A., Trifilio, S., Tallman, M., Bennett, C., Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 40 (2007), 185–192.
28. + Treg expansion. Am J Transplant 13 (2013), 3123–3131.
29. Park, M.-J., Lee, S.-H., Kim, E.-K., Lee, E.-J., Park, S.-H., Kwok, S.-K., Cho, M.-L., Myeloid-derived suppressor cells induce the expansion of regulatory b cells and ameliorate autoimmunity in the Sanroque mouse model of systemic lupus erythematosus. Arthritis Rheumatol 68 (2016), 2717–2727.
30. Green, K.A., Cook, W.J., Green, W.R., Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency. J Virol 87 (2013), 2058–2071.
31. Highfill, S.L., Rodriguez, P.C., Zhou, Q., Goetz, C.A., Koehn, B.H., Veenstra, R., Taylor, P.A., Panoskaltsis-Mortari, A., Serody, J.S., Munn, D.H., et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116 (2010), 5738–5747.
32. Fujii, W., Ashihara, E., Hirai, H., Nagahara, H., Kajitani, N., Fujioka, K., Murakami, K., Seno, T., Yamamoto, A., Ishino, H., et al. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol 191 (2013), 1073–1081.
33. Zhang, L., Zhang, Z., Zhang, H., Wu, M., Wang, Y., Myeloid-derived suppressor cells protect mouse models from autoimmune arthritis via controlling inflammatory response. Inflammation 37 (2014), 670–677.
34. Messmann, J.J., Reisser, T., Leithauser, F., Lutz, M.B., Debatin, K.-M., Strauss, G., In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity. Blood 126 (2015), 1138–1148.
35. Koehn, B.H., Apostolova, P., Haverkamp, J.M., Miller, J.S., McCullar, V., Tolar, J., Munn, D.H., Murphy, W.J., Brickey, W.J., Serody, J.S., et al. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood 126 (2015), 1621–1628.
36. Nakamura, T., Nakao, T., Yoshimura, N., Ashihara, E., Rapamycin prolongs cardiac allograft survival in a mouse model by inducing myeloid-derived suppressor cells. Am J Transplant 15 (2015), 2364–2377.
37. Morales, J.K., Kmieciak, M., Knutson, K.L., Bear, H.D., Manjili, M.H., GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 123 (2010), 39–49.
38. Kurkó, J., Vida, A., Ocskó, T., Tryniszewska, B., Rauch, T.A., Glant, T.T., Szekanecz, Z., Mikecz, K., Suppression of proteoglycan-induced autoimmune arthritis by myeloid-derived suppressor cells generated in vitro from murine bone marrow. PLOS ONE, 9, 2014, e111815.
39. Dufait, I., Schwarze, J.K., Liechtenstein, T., Leonard, W., Jiang, H., Escors, D., De Ridder, M., Breckpot, K., Dufait, I., Schwarze, J.K., et al. Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget 6 (2015), 12369–12382.
40. Casacuberta-Serra, S., Parés, M., Golbano, A., Coves, E., Espejo, C., Barquinero, J., Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes. Immunol Cell Biol 95 (2017), 538–548.
41. Giallongo, C., Tibullo, D., Parrinello, N.L., Cava, P. La, Rosa, M. Di, Bramanti, V., Raimondo, C. Di, Conticello, C., Chiarenza, A., Palumbo, G.A., et al. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget 7 (2016), 85764–85775.
42. Tebartz, C., Horst, S.A., Sparwasser, T., Huehn, J., Beineke, A., Peters, G., Medina, E., A major role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immunosuppression during Staphylococcus aureus infection. J Immunol 194 (2015), 1100–1111.
43. El Daker, S., Sacchi, A., Tempestilli, M., Carducci, C., Goletti, D., Vanini, V., Colizzi, V., Lauria, F.N., Martini, F., Martino, A., Granulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level. PLOS ONE, 10, 2015, e0123772.
44. du Plessis, N., Loebenberg, L., Kriel, M., von Groote-Bidlingmaier, F., Ribechini, E., Loxton, A.G., van Helden, P.D., Lutz, M.B., Walzl, G., Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med 188 (2013), 724–732.
45. Speigl, L., Burow, H., Bailur, J.K., Janssen, N., Walter, C.-B., Pawelec, G., Shipp, C., CD14+ HLA-DR−/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation. Breast Cancer Res Treat, 2017, 10.1007/s10549-017-4594-9.
46. Ish-Shalom, E., Meirow, Y., Sade-Feldman, M., Kanterman, J., Wang, L., Mizrahi, O., Klieger, Y., Baniyash, M., Impaired SNX9 expression in immune cells during chronic inflammation: prognostic and diagnostic implications. J Immunol 196 (2016), 156–167.
47. Ku, A.W., Muhitch, J.B., Powers, C.A., Diehl, M., Kim, M., Fisher, D.T., Sharda, A.P., Clements, V.K., O'Loughlin, K., Minderman, H., et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife 5 (2016), 1–29.
48. Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcène, A., Van Valckenborgh, E., Baron, F., Beguin, Y., Caers, J., et al. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget 7 (2016), 37931–37943.
49. Liu, J., Wang, H., Yu, Q., Zheng, S., Jiang, Y., Liu, Y., Yuan, G., Qiu, L., Aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in non small cell lung carcinoma patients. Hum Immunol 77 (2016), 84–89.
50. Sarhan, D., Cichocki, F., Zhang, B., Yingst, A., Spellman, S.R., Cooley, S., Verneris, M.R., Blazar, B.R., Miller, J.S., Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res 76 (2016), 5696–5706.
51. Mueller-Leisse, J., Brueggemann, S., Bouzani, M., Schmitt, A.-L., Einsele, H., Loeffler, J., Polymorphonuclear neutrophils and granulocytic myeloid-derived suppressor cells inhibit natural killer cell activity toward Aspergillus fumigatus. Med Mycol 53 (2015), 622–629.
52. Lelis, F.J.N., Jaufmann, J., Singh, A., Fromm, K., Teschner, A.C., Pöschel, S., Schäfer, I., Beer-Hammer, S., Rieber, N., Hartl, D., Myeloid-derived suppressor cells modulate B-cell responses. Immunol Lett 188 (2017), 108–115.
53. Sawant, A., Deshane, J., Jules, J., Lee, C.M., Harris, B.A., Feng, X., Ponnazhagan, S., Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res 73 (2013), 672–682.